Can the brain grow neurons later in life? For now, the answer is ‘maybe’

In the past month, two studies came to very different conclusions when examining if the human brain is capable of growing new neurons later in life. The first, published March 7 in Nature, found no evidence of neurogenesis in individuals older than 13 years old. But another study, released April 5 in Cell Stem Cell, claimed to find neuron generation in all the brains examined.

The question, for now, appears to still be open.

The latest study was conducted by a team from Columbia University, using brains donated after death from 26 people ranging in age from 14 to 79.

“[H]ealthy older subjects without cognitive impairment, neuropsychiatric disease or treatment display preserved neurogenesis,” wrote Maura Boldrini, MD, PhD, et al. “It is possible that ongoing hippocampal neurogenesis sustains human-specific cognitive function throughout life and that declines may be linked to compromised cognitive-emotional resilience.”

The researchers examined dentate gyrus, a part of the hippocampus that is thought to produce new neurons.

The results of the Nature study, however, appear to directly contradict Boldrini’s team. Lead author Shawn F. Sorrells—with the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at University of California San Francisco—and colleagues examined 59 brains and found no neurogenesis in brains past the age of 13.

“We conclude that recruitment of young neurons to the primate hippocampus decreases rapidly during the first years of life, and that neurogenesis in the dentate gyrus does not continue, or is extremely rare, in adult humans,” Sorrells et al. wrote.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.